Evaxion A/S
EVAX Nasdaq· Biological Products, (No Diagnostic Substances)
KIRA · Stoqly’s AI analyst, in plain words
- Evaxion A/S had $7.5M of revenue in fiscal 2025, up 125.1% on the year before.
- Its operating margin was −122.7%, up 317.9 pts: of every 100 in sales, about −123 is left after running the business.
- Evaxion A/S lost $7.7M in fiscal 2025.
- Free cash flow was −$6.6M in fiscal 2025, −88.2% of revenue.
- Evaxion A/S has $17.7M more cash than debt.
Market cap
—
P/E
—
Revenue
$7.5M
Net income
−$7.7M
Free cash flow
−$6.6M
Operating margin
−122.7%
Evaxion A/S in 30 seconds · fiscal 2025
Are sales growing?
+125.1%
Yes. Sales grew 125.1% last year.
Does it make a profit?
−102.4%
No. It lost money last year.
Does profit turn into cash?
−88.2%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
What Evaxion A/S does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 5, 2026
- Legal name
- Evaxion A/S
- CIK
- 0001828253
Evaxion A/S · EVAX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $0.1M | $3.3M | $7.5M |
| Revenue growth | — | — | — | 4,480.8% | 125.1% |
| Operating margin | — | — | −30,406.8% | −440.6% | −122.7% |
| Net income | −$24.5M | −$23.2M | −$22.1M | −$10.6M | −$7.7M |
| Net margin | — | — | −30,308.2% | −316.0% | −102.4% |
| Diluted EPS | −$63.00 | −$49.00 | −$40.50 | — | — |
| Cash | |||||
| Cash from operations | −$21.9M | −$25.8M | −$17.7M | −$12.9M | −$6.6M |
| Capital expenditure | $1.3M | $0.3M | $0.1M | $0.0M | $0.0M |
| Free cash flow | −$23.2M | −$26.1M | −$17.8M | −$12.9M | −$6.6M |
| FCF margin | — | — | −24,353.4% | −387.0% | −88.2% |
| Share count change | 26.3% | 21.3% | 15.6% | 96.3% | 497.3% |
| Debt and strength | |||||
| Cash and short-term investments | $32.2M | $13.2M | $5.6M | $6.0M | $23.2M |
| Debt incl. finance leases | $1.2M | $8.0M | $8.6M | $8.2M | $5.5M |
| Shareholders' equity | $32.4M | $8.3M | −$4.7M | −$1.7M | $17.0M |
| Current ratio | 8.0x | 4.5x | 1.2x | 2.0x | 5.8x |
| Interest coverage | −5,166.8x | −743.1x | −22,197.0x | — | — |
| Returns and quality | |||||
| Return on capital | −1,416.3% | −639.9% | — | −2,067.2% | — |
| Return on equity | −124.3% | −113.7% | −1,238.1% | — | −100.2% |
| Return on tangible equity | −75.8% | −279.0% | — | — | −45.2% |
| Piotroski F-score | — | 0 | 2 | 4 | 4 |
| Altman Z'' | 1.0 | −15.8 | −38.5 | −36.7 | −10.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Evaxion A/S · EVAX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001828253). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.